Logo image of QNCX

QUINCE THERAPEUTICS INC (QNCX) Stock Fundamental Analysis

NASDAQ:QNCX - Nasdaq - US22053A1079 - Common Stock - Currency: USD

1.51  +0.01 (+0.67%)

Fundamental Rating

2

Taking everything into account, QNCX scores 2 out of 10 in our fundamental rating. QNCX was compared to 572 industry peers in the Biotechnology industry. QNCX has a bad profitability rating. Also its financial health evaluation is rather negative. QNCX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

QNCX had negative earnings in the past year.
QNCX had a negative operating cash flow in the past year.
In the past 5 years QNCX always reported negative net income.
In the past 5 years QNCX always reported negative operating cash flow.
QNCX Yearly Net Income VS EBIT VS OCF VS FCFQNCX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M -80M

1.2 Ratios

QNCX has a Return On Assets of -42.10%. This is comparable to the rest of the industry: QNCX outperforms 53.75% of its industry peers.
QNCX has a Return On Equity (-118.54%) which is in line with its industry peers.
Industry RankSector Rank
ROA -42.1%
ROE -118.54%
ROIC N/A
ROA(3y)-45.31%
ROA(5y)-41.24%
ROE(3y)-54.69%
ROE(5y)-48.14%
ROIC(3y)N/A
ROIC(5y)N/A
QNCX Yearly ROA, ROE, ROICQNCX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 0 100 -100 200 300

1.3 Margins

QNCX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
QNCX Yearly Profit, Operating, Gross MarginsQNCX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023

More info and screens

3

2. Health

2.1 Basic Checks

The number of shares outstanding for QNCX has been increased compared to 1 year ago.
Compared to 5 years ago, QNCX has more shares outstanding
Compared to 1 year ago, QNCX has a worse debt to assets ratio.
QNCX Yearly Shares OutstandingQNCX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
QNCX Yearly Total Debt VS Total AssetsQNCX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -4.09, we must say that QNCX is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -4.09, QNCX is in line with its industry, outperforming 42.76% of the companies in the same industry.
A Debt/Equity ratio of 0.33 indicates that QNCX is not too dependend on debt financing.
The Debt to Equity ratio of QNCX (0.33) is worse than 71.55% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.33
Debt/FCF N/A
Altman-Z -4.09
ROIC/WACCN/A
WACCN/A
QNCX Yearly LT Debt VS Equity VS FCFQNCX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M 150M

2.3 Liquidity

A Current Ratio of 9.53 indicates that QNCX has no problem at all paying its short term obligations.
QNCX has a Current ratio of 9.53. This is in the better half of the industry: QNCX outperforms 79.41% of its industry peers.
A Quick Ratio of 9.53 indicates that QNCX has no problem at all paying its short term obligations.
QNCX has a Quick ratio of 9.53. This is in the better half of the industry: QNCX outperforms 79.41% of its industry peers.
Industry RankSector Rank
Current Ratio 9.53
Quick Ratio 9.53
QNCX Yearly Current Assets VS Current LiabilitesQNCX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for QNCX have decreased strongly by -59.76% in the last year.
EPS 1Y (TTM)-59.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, QNCX will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.22% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y60.13%
EPS Next 2Y33.4%
EPS Next 3Y21.43%
EPS Next 5Y19.22%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
QNCX Yearly Revenue VS EstimatesQNCX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
QNCX Yearly EPS VS EstimatesQNCX Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

QNCX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year QNCX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
QNCX Price Earnings VS Forward Price EarningsQNCX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
QNCX Per share dataQNCX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as QNCX's earnings are expected to grow with 21.43% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.4%
EPS Next 3Y21.43%

More info and screens

0

5. Dividend

5.1 Amount

QNCX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

QUINCE THERAPEUTICS INC

NASDAQ:QNCX (3/7/2025, 8:00:01 PM)

1.51

+0.01 (+0.67%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-04 2025-03-04/amc
Earnings (Next)05-12 2025-05-12
Inst Owners22.27%
Inst Owner ChangeN/A
Ins Owners13.07%
Ins Owner Change0%
Market Cap66.44M
Analysts82.22
Price Target9.18 (507.95%)
Short Float %6.74%
Short Ratio20.31
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-5.05%
EPS NY rev (1m)0%
EPS NY rev (3m)1.23%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.48
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.25
EYN/A
EPS(NY)-0.68
Fwd EYN/A
FCF(TTM)-0.69
FCFYN/A
OCF(TTM)-0.69
OCFYN/A
SpS0
BVpS1.02
TBVpS-0.45
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -42.1%
ROE -118.54%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-45.31%
ROA(5y)-41.24%
ROE(3y)-54.69%
ROE(5y)-48.14%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.33
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 30.51%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.53
Quick Ratio 9.53
Altman-Z -4.09
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)55.88%
Cap/Depr(5y)42.87%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-59.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.33%
EPS Next Y60.13%
EPS Next 2Y33.4%
EPS Next 3Y21.43%
EPS Next 5Y19.22%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-52.01%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-72.14%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y42.16%
OCF growth 3YN/A
OCF growth 5YN/A